Literature DB >> 32421492

Mycoplasma pneumoniae biofilms grown in vitro: traits associated with persistence and cytotoxicity.

Monica Feng1, Andrew C Schaff2, Mitchell F Balish3.   

Abstract

The atypical bacterial pathogen Mycoplasma pneumoniae is a leading etiological agent of community-acquired pneumonia in humans; infections are often recalcitrant, recurrent and resistant to antibiotic treatment. These characteristics suggest a mechanism that facilitates long-term colonization in hosts. In an in vitro setting, M. pneumoniae forms biofilms that are unusual in that motility plays no more than a very limited role in their formation and development. Given the unusual nature of M. pneumoniae biofilms, open questions remain concerning phenotypes associated with persistence, such as what properties might favour the bacteria while minimizing host damage. M. pneumoniae also produces several cytotoxic molecules including community-acquired respiratory distress syndrome (CARDS) toxin, H2S and H2O2, but how it deploys these agents during growth is unknown. Whereas several biochemical techniques for biofilm disruption were ineffective, sonication was required for disruption of M. pneumoniae biofilms to generate individual cells for comparative studies, suggesting unusual physical properties likely related to the atypical cell envelope. Nonetheless, like for other bacteria, biofilms were less susceptible to antibiotic inhibition and complement killing than dispersed cells, with resistance increasing as the biofilms matured. CARDS toxin levels and enzymatic activities associated with H2S and H2O2 production were highest during early biofilm formation and decreased over time, suggesting attenuation of virulence in connection with chronic infection. Collectively, these findings result in a model of how M. pneumoniae biofilms contribute to both the establishment and propagation of M. pneumoniae infections, and how both biofilm towers and individual cells participate in persistence and chronic disease.

Entities:  

Keywords:  Mycoplasma pneumoniae; antibiotic resistance; biofilm; complement; cytotoxicity; persistence

Mesh:

Substances:

Year:  2020        PMID: 32421492     DOI: 10.1099/mic.0.000928

Source DB:  PubMed          Journal:  Microbiology (Reading)        ISSN: 1350-0872            Impact factor:   2.777


  6 in total

Review 1.  Mycoplasmas as Host Pantropic and Specific Pathogens: Clinical Implications, Gene Transfer, Virulence Factors, and Future Perspectives.

Authors:  Ali Dawood; Samah Attia Algharib; Gang Zhao; Tingting Zhu; Mingpu Qi; Kong Delai; Zhiyu Hao; Marawan A Marawan; Ihsanullah Shirani; Aizhen Guo
Journal:  Front Cell Infect Microbiol       Date:  2022-05-13       Impact factor: 6.073

Review 2.  Infection strategies of mycoplasmas: Unraveling the panoply of virulence factors.

Authors:  Chen Yiwen; Wu Yueyue; Qin Lianmei; Zhu Cuiming; You Xiaoxing
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

3.  Molecular Basis of the Slow Growth of Mycoplasma hominis on Different Energy Sources.

Authors:  Daria V Evsyutina; Tatiana A Semashko; Maria A Galyamina; Sergey I Kovalchuk; Rustam H Ziganshin; Valentina G Ladygina; Gleb Y Fisunov; Olga V Pobeguts
Journal:  Front Cell Infect Microbiol       Date:  2022-07-07       Impact factor: 6.073

4.  Visualisation and biovolume quantification in the characterisation of biofilm formation in Mycoplasma fermentans.

Authors:  Ammar A Awadh; Alison F Kelly; Gary Forster-Wilkins; David Wertheim; Richard Giddens; Simon W Gould; Mark D Fielder
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

5.  Microbial Musings - July 2020.

Authors:  Gavin H Thomas
Journal:  Microbiology (Reading)       Date:  2020-07       Impact factor: 2.777

6.  Mycoplasma genitalium Biofilms Contain Poly-GlcNAc and Contribute to Antibiotic Resistance.

Authors:  James M Daubenspeck; Arthur H Totten; Jason Needham; Monica Feng; Mitchell F Balish; T Prescott Atkinson; Kevin Dybvig
Journal:  Front Microbiol       Date:  2020-10-27       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.